Oppositely to ERα, this receptor exerts anti-proliferative effects in the prostate, suggesting that ERβ agonists may be useful tools to counteract PCa, avoiding side effects of SERM [246]. The gene discussed is ESR1; the disease is posterior cortical atrophy.